Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)

被引：0
作者：
Aransay, N. Reguart [1 ]
Sanchez, J. [1 ]
Vidal, O. J. Juan [2 ]
Domingo, M. Aguilo [3 ]
Arriola, E. [4 ]
Lopez, C. [2 ]
Botella, X. [3 ]
Cots, F. [4 ]
Montironi, C. [5 ]
Palanca, S.
Borras, E. [3 ]
Pinto, L. Masfarre [4 ]
Planellas, L. [6 ]
Vila, A. Lloansi [6 ]
机构：
[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[2] Hosp Univ Politecn La Fe, Dept Med Oncol, Valencia, Spain
[3] Hosp Terrassa Consorci Sanitari Terrassa, Med Oncol, Terrassa, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Clin Barcelona, Pathol, Barcelona, Spain
[6] Amgen Spain, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1410P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer
    Sayama, Hiroyuki
    Marcantonio, Diana
    Nagashima, Takeyuki
    Shimazaki, Masashi
    Minematsu, Tsuyoshi
    Apgar, Joshua F.
    Burke, John M.
    Wille, Lucia
    Nagasaka, Yasuhisa
    Kirouac, Daniel C.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 864 - 877
  • [42] NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, Stephen
    Snzol, Mario
    Harbison, Christopher T.
    Kollia, Gerogia D.
    Gupta, Ashok
    Gettinger, Scott N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 157 - 157
  • [43] Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions
    Scharpenseel, Heather
    Stickelmann, Andreas
    Siemanowski, Janna
    Malchers, Florian
    Scheffler, Matthias
    Hillmer, Axel
    Meemboor, Sonja
    Merkelbach-Bruse, Sabine
    Scheel, Andreas H.
    Riedel, Richard
    Friedrich, Sebastian Yves
    Eisert, Michels Anna
    Fischer, Rieke Nila
    Brodersen, Marlene
    Thomas, Roman K.
    Buettner, Reinhard
    Graeven, Ullrich
    Kosse, Nils
    Nogova, Lucia
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Weight loss affects outcome in KrasG12C non-small cell lung cancer first line treated patients.
    Fancelli, Sara
    Caliman, Enrico
    Pillozzi, Serena
    Napolitano, Brunella
    Pieroni, Edoardo
    Mazzoni, Francesca
    Paglialunga, Luca
    Michelet, Marta Rita Gatta
    Roviello, Giandomenico
    Castiglione, Francesca
    Bartoli, Caterina
    Antonuzzo, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Efficacy and Safety of Icotinib in Advanced Non-Small-Cell Lung Cancer Patients Harboring Uncommon EGFR Mutation: a Retrospective Analysis
    Yuan, Xiaobin
    Wang, Yang
    Yang, Min
    Shen, Zhilin
    Chen, Hui
    He, Xiangbo
    Ma, Yongbin
    Ding, Lieming
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (01): : 46 - 53
  • [46] Use of gefitinib ('Iressa', ZD1839) in advanced non-small-cell lung cancer for routine clinical practice
    Bendel, J
    Häusler, J
    Korfee, S
    Antoch, G
    Gauler, T
    Eberhardt, W
    BRITISH JOURNAL OF CANCER, 2003, 89 : S25 - S25
  • [47] CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
    Hong, David S.
    Kuo, James
    Sacher, Adrian G.
    Barlesi, Fabrice
    Besse, Benjamin
    Kuboki, Yasutoshi
    Dy, Grace K.
    Dembla, Vikas
    Krauss, John C.
    Burns, Timothy F.
    Kim, June
    Henary, Haby
    Ngarmchamnanrith, Gataree
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
    Janne, P. A.
    Rybkin, I. I.
    Spira, A. I.
    Riely, G. J.
    Papadopoulos, K. P.
    Sabari, J. K.
    Johnson, M. L.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Leal, T. A.
    Velastegui, K.
    Cornelius, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Ou, S. H. I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S2
  • [49] Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.
    May, Michael S.
    Wooster, Margaux
    May, Benjamin
    Shu, Catherine A.
    Henick, Brian S.
    Stoopler, Mark
    Smith-Marrone, Stephanie
    Saqi, Anjali
    Mansukhani, Mahesh M.
    Riely, Gregory J.
    Hershman, Dawn L.
    Herzberg, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Gaillard, V. E.
    Brugger, W.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1375 - 1383
12345